Significant Publications on Infectious Diseases Pharmacotherapy in 2022.

Autor:	Teran N; Department of Pharmacy, CHI Baylor St Luke's Medical Center, Houston, TX, USA., Buckley V; Department of Pharmacy, The University of Texas Medical Branch, Galveston, TX, USA., Britt RS; Department of Pharmacy, The University of Texas Medical Branch, Galveston, TX, USA., Ikwuagwu J; Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA., Thomas JL; Department of Pharmacy, Memorial Hermann Southwest, Houston, TX, USA., Zaki A; Department of Pharmacy, Memorial Hermann Katy Hospital, Katy, TX, USA., Olson K; Department of Pharmacy, HCA Houston Healthcare Clear Lake, Webster, TX, USA., Stramel S; Department of Pharmacy, Memorial Hermann Memorial City Medical Center, Houston, TX, USA.
Jazyk:	angličtina
Zdroj:	Journal of pharmacy practice [J Pharm Pract] 2024 Aug; Vol. 37 (4), pp. 995-1007. Date of Electronic Publication: 2023 Sep 14.
DOI:	10.1177/08971900231194200
Abstrakt:	Purpose: To provide summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2022. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2022. Article nominations included those pertaining to general ID, as well as those including coronavirus disease 2019 (COVID-19), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. A total of 71 articles were nominated by HIDN. Members: 68 articles pertaining to general ID pharmacotherapy and 3 articles focusing on HIV/AIDS. To aid selection of the most these most notable articles of 2022, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 128 recorded votes for the top 10 general ID pharmacotherapy articles and 30 votes recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Post pandemic significant advances in antimicrobial stewardship and infectious disease states continues to occur in a world recently focused on the coronavirus disease 2019 (COVID-19) global pandemic. Continuous growth in publication of ID-related articles over the past year lends towards the aims of this review to aid clinicians in remaining current on key practice-changing ID pharmacotherapy publications from 2022. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu